Changes in the Impact of Genitourinary Syndrome of Menopause With a Novel Nonhormonal Vulvovaginal Gel Assessed by PROMs.

Inclusion Criteria: * Patient has to have at least one symptom of GSM or suffer from symptoms related to vulvovaginal atrophy (as evidenced by gynecological examination with a Vaginal Health Index ≤15). * Patient must be postmenopausal with at least 1 year without a menstrual period. * Patient must consider that her quality of life is affected by GSM symptoms * Patient not followed due to any gynecological disease. * All participants must be able to understand and to fill in the self-reported questionnaires. Exclusion Criteria: * Patients that do not want to fill the questionnaire, especially the questions that address sexual functioning. * Participants that use any oral products containing hormones or estrogen receptor modulators for the past 8 weeks, nor vaginal topical hormone products within 4 weeks, neither prescription nor non-prescription therapies for GSM, including topical vaginal non-hormonal lubricants or moisturizers for the last week. * Patients with history of vulvar, vaginal and/or cervical malignancy. * Patients having received radiotherapy treatment in the pelvic and/or genital region. * Patients with any type of disease that causes alteration of collagenogenesis. * Patients that use cytotoxic drugs leading to mucositis and alterations of tissue regeneration in the last 6 months. * Patients having received laser and/or radiofrequency treatment for handling genital atrophy or other pelvic floor dysfunctions. * Patients with active urinary and/or genital tra…